List view / Grid view
The challenge of efficiently delivering a drug to its site of action, while maintaining its efficacy and minimising its potential toxicity, has received much attention in recent years, with the growing use of complex and often delicate biological molecules as therapeutic agents...
EPR Editor Steve Bremer discusses drug delivery through the skin with Shashank Jain, Formulation Research Scientist at G&W Laboratories.
Following the introduction of the concept of mucoadhesion in the 1980s, polymeric excipients became attractive for intense research purposes. Mucosal delivery as a non-invasive delivery pathway raised the bar.
30 May 2017 | By Pasi Kemppainen, Executive Consultant, Pharma Digitalisation and Sammeli Liikkanen, Chief Digital Officer, Orion Pharma
Pharma Digitalisation Executive Consultant, Pasi Kemppainen, and Orion’s CDO Sammeli Liikkanen talk technologies, challenges and opportunities with the digitalisation of pharma…
26 May 2017 | By Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare
We caught up with Celltrion Healthcare's Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…
17 May 2017 | By Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA
We caught up with Janssen's Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma...
10 May 2017 | By Cristina Arnés, IFPMA Policy Analyst, Regulatory Policy and Economic Affairs
IFPMA's top analyst examines future trends, biotherapeutics and personalised medicine, and explains why the industry needs to examine its economic footprint...
3 May 2017 | By Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim
With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP to find out more…
The Directive on Falsified Medicines (FMD, or Directive 2011/62/EU amending Directive 2001/83/EC) and its supplementing Delegated Regulation (DR 2016/161) aim to improve patient safety by preventing falsified medicines from entering the legal supply chain...
European Pharmaceutical Review caught up with Richmond Pharmacology’s CEO, Dr Jorg Taubel, to talk pioneering UK based first-in-human clinical trials…
21 April 2017 | By Ben van der Schaaf, Principal at Arthur D. Little
Ben van der Schaaf explains how collaborative work can fund clinical trials of de-prioristised drugs and why pharma should consider partnering up...
Plastic materials used in pharmaceutical packaging can interact with the packaged dosage form, causing leachables to accumulate...
Guardino (2005) identified the first rapid microbiological method as a rapid plate count technique. This method was developed by Professor Frost...
Gas chromatography (GC) predates the more commonly utilised high performance liquid chromatography (HPLC). However, GC continues to enjoy some important niche applications in modern pharmaceutical analysis, such as the analysis of residual solvents or volatile organic compounds (VOCs)...
The concept of Quality by Design (QbD) was implemented by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and United States Food and Drug Administration (FDA) around a decade ago, with the aim of adopting systematic approaches for developing high-quality pharmaceutical products for patients’…
